Synthesis, Structure, Electrochemistry, and Spectral Characterization of Bis-Isatin Thiocarbohydrazone Metal Complexes and Their Antitumor Activity Against Ehrlich Ascites Carcinoma in Swiss Albino Mice

Table 7

Effect of the compounds on hematological parameters.

Group	Dose	RBC	Hb	WBC	Differential Leucocyte Count %
	(mg/kg)	(Mean ± SE)	(Mean ± SE)	(Mean ± SE)
		(Millions/mm^3)	(g%)	(10^3cells/ mm^3)	Lymphocytes	Neutrophils	Monocytes
Normal	—	5.03±0.28	15.72±0.32	8.59±0.16	86.23±0.61	13.03±0.46	1.07±0.33
Control	—	2.14±0.34^a,c	9.53±0.32^a,c	32.31±0.67^a,c	41.80±0.39^a,c	57.35±0.61^a,c	1.25±0.43
Cisplatin	3.5	3.26±0.24^a,b	13.08±0.29^a,b	10.90±0.19^a,b	77.97±0.48^a,b	20.80±0.47^b	1.22±0.54
[Cu(L)Cl]⋅2H2O	50	3.84±0.51^a,b,c	11.71±0.29^a,b,c	17.84±0.31^a,b,c	68.97±0.20^a,b,c	29.72±0.22^a,b	1.32±0.31
[Cu(L)OAc]⋅2H2O	50	4.49±0.30^a,b,c	12.79±0.17^a,b,c	19.27±0.99^a,b,c	68.10±0.45^a,b,c	30.55±0.47^a,b	1.35±0.43
Ligand	50	4.72±0.11^a,b,c	11.92±0.15^a,b,c	22.33±0.93^a,b,c	62.78±0.27^a,b,c	35.92±0.28^a,b,c	1.30±0.63

a 𝑃<.05 versus normal.
b 𝑃<.05 versus control mice.
c𝑃<.05 versus cisplatin.